London UK, 5th December 2013: Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, reports the appointment of Oliver Boucher to its Board of Directors. Oliver Boucher brings considerable corporate expertise and knowledge to the Company gained over two decades in the sector with senior executive roles at GSK, Trigen, Sigmoid and more recently as the Chief Business Officer at Vivacta.
Dr Salman Rahman, CEO and co-founder of Vasgen said: “Oliver is an exceptional life science executive and we are delighted to have him as part of our team. Oliver’s experience and knowledge of the sector will prove extremely important in facilitating Vasgen’s development as an innovative biotech.” Dr Yatin Patel, COO and co-founder of Vasgen commented “We are very pleased that Oliver has joined Vasgen and we look forward to working closely with him to develop our R & D programmes.
-Ends-
Notes to Editors
Vasgen Limited is a new London-based biotech company developing innovative ocular and cancer therapeutics to meet unmet clinical needs. The Company’s technologies include AbIMP®, a novel antibody-based approach allowing development of highly selective inhibitors of metalloproteinase catalytic activity with a particular focus on the ADAMs gene family of sheddases. The Company’s lead product under development is a pre-clinical stage therapeutic AbIMP targeting ADAM15 for anti-angiogenesis therapy. More information is available at www.vasgen.co.uk
For further information please contact:
Tel : +44 (0)207 691 2149
info@vasgen.co.uk